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Abstract: Age-related bone loss in men is a poorly understood phenomenon, although increasing 
data on the pathophysiology of bone in men is becoming available. Most of what we know on 
bone pathophysiology derives from studies on women. The well-known association between 
menopause and osteoporosis is far from been disproven. However, male osteoporosis is a 
relatively new phenomenon. Its novelty is in part compensated for by the number of studies on 
female osteoporosis and bone pathophysiology. On the other hand, the deeper understanding of 
female osteoporosis could lead to an underestimation of this condition in the male counterpart. 
The longer life-span exposes a number of men to the risk of mild-to-severe hypogonadism 
which in turn we know to be one of the pathogenetic steps toward the loss of bone mineral 
content in men and in women. Hypogonadism might therefore be one among many corrigible 
risk factors such as cigarette smoking and alcohol abuse against which clinicians should act in 
order to prevent osteoporosis and its complications. Treatments with calcium plus vitamin D 
and bisphophonates are widely used in men, when osteoporosis is documented and hypogo-
nadism has been excluded. The poor knowledge on male osteoporosis accounts for the lack of 
well shared protocols for the clinical management of the disease. This review focuses on the 
clinical approach and treatment strategy for osteoporosis in men with particular attention to its 
relationship with male hypogonadism.
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The osteoporotic male, perhaps an overlooked 
and under managed disease
Osteoporosis in men is strictly related to advancing age, the onset being more advanced 
when compared with females (Rochira et al 2006). The onset of osteoporosis in men 
is usually at a more advanced age than in women, and is strictly related to aging 
(Rochira et al 2006).
The measurement of bone mineral density (BMD) is considered the most 
appropriate clinical tool for the diagnosis of male osteoporosis (osteoporosis when 
the t-score is lower than 2.5 S.D. and severe osteoporosis when osteoporotic fractures 
are present) (Consensus Development Conference 1993). Reference values for normal 
BMD in men are borrowed from women (Rochira et al 2006), based on the assumption 
that female standards could also be more or less adequate for the male population 
(Orwoll and Klein 1995; Bilezikian 1999). As a consequence the relationships be-
tween BMD measurement and the risk of fractures in men remain controversial. In 
clinical practice, physicians hold poor tools for the management of male osteoporosis 
since BMD represents only a surrogate to infer the fracture risk, it does not account 
for bone quality and bone resistance to fracture, and, lastly, the knowledge of bone 
pathophysiology is still incomplete in men. In contrast to the treatment of women, 
osteoporosis in men is often overlooked, and more efforts are needed for both clinical 
and basic research on this condition in men (Rochira et al 2006).
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Clinical care for male osteoporosis is based on treatments 
which were fi rst developed for postmenopausal women and 
only later became available for males. This approach results 
in uncertainties in the management of the osteoporotic man 
since evidence-based data is insuffi cient to state whether men 
may benefi t from treatment found effi cacious in women, or 
whether the dosage used in females is also adequate in men. 
Again, therapeutic trials have mainly focused on women 
leaving some drugs untested in men (eg, strontium ranelate). 
For this reason the number of treatments accessible for 
male osteoporosis is fewer than in women and differences 
in the approval of drug use for men are present between 
some geographic areas (eg, teriparatide is not available for 
men in Europe). All these controversies merely refl ect an 
underestimation of the real impact of male osteoporosis, 
which has been disregarded for a long time (Rochira et al 
2006). In the past, furthermore, clinicians have focused their 
attention on female osteoporosis, which has been considered 
as ‘epidemic’. True awareness of the prevalence of osteo-
porosis in men, of its pathophysiology and of the severity 
of consequences due to fracture (morbidity and mortality) 
often remains unnoticed.
This review focuses on bone physiology and pathophysi-
ology in men, but with particular attention to the management 
of male osteoporosis.
Summary of natural history 
and clinical presentation of male 
osteoporosis
Both the onset of osteoporosis (Orwoll and Klein 1995) and 
the occurrence of fractures are delayed in men (Donaldson 
et al 1990), the latter rarely occurring before 70 yrs 
(Bilezikian 1999).
Generally, fractures may have severe implications: a 
proximal femur or vertebral fracture in an aged man is an 
event that often leads to permanent disability because of the 
small chance of recovery. Accordingly the mortality rate, 
within 5-years of an event, is signifi cantly greater in men 
than in women (about 3:2) (Center et al 1999).
Bone mineral content preservation is more prolonged 
in men than in women, accounting for the late-onset of 
osteoporosis in the human male. It is well known that the 
same degree of bone loss is associated with a lower risk of 
fracture in men than in women as a consequence of a higher 
resistance to fracture of male bone (Bilezikian 1999; Seeman 
2002; Seeman and Delmas 2006). This important aspect of 
the natural history of the disease is due to sexual dimorphic 
differences in bone structure and stiffness (Seeman 2002; 
Duan et al 2003). In addition, sex-differences in the natural 
history of bone accrual (a physiological event) and bone loss 
(a pathophysiological process) account for the discrepancy 
between the two sexes due to exposure to different sex 
steroids, which act in a dimorphic fashion on bone, especially 
at puberty (Duan et al 2003). The results are differences in 
bone (micro)structure and bone quality (Seeman 2002; Duan 
et al 2003). Obviously, in adulthood bone mineral content 
is the net result of baseline bone mass achieved at the end 
of puberty (bone accrual), and of the subsequent bone loss 
(bone resorption).
Despite confl icting results (Riggs et al 2004), a gender 
difference in bone size, consisting of a greater cortical bone 
width in men, exists, and is probably related to the greater 
amount of androgens in men at puberty, and during adulthood 
as well (Seeman 2002; Duan et al 2003). Thus men develop 
a greater bone mass during puberty than women do.
Thereafter age-related changes in bone mass lead to 
progressive loss of the bone mass. This consists of a decrease 
in BMD with advancing age at both cancellous and cortical 
sites (Riggs et al 1998). These changes are sexually dimor-
phic particularly in cancellous bone (rapid accelerated bone 
loss after menopause only in women). In men bone loss 
occurs later in life than in women (Rochira et al 2006) and 
this phenomenon increases progressively with advancing 
age, particularly in cancellous bone after the age of 70 years 
(Riggs et al 1998; Rochira et al 2006). Serum testosterone 
– the bioavailable fraction – declines slowly in men with 
age, according to the development of a mild age-related 
hypogonadism (Swerdloff and Wang 2002), whereas the 
sex-steroid defect is severe in postmenopausal women. 
Age-related osteoporosis is strictly related to the progres-
sive decline of the hypothalamic – pituitary – gonadal axis 
function in men (Riggs et al 1998). The continuous slow 
reduction in circulating androgens, as well as changes in total 
and bioavailable serum testosterone, are strongly related to 
bone loss (Bilezikian 1999; Boonen and Vanderschueren 
2002). Thus the decrease in BMD depends on age-related 
hypogonadism and circulating androgens, particularly the 
bioavailable quota (Slemenda et al 1997; Khosla et al 1998; 
Kenny et al 2000; Scopacasa et al 2000; Amin et al 2000; 
Khosla et al 2001a; Khosla et al 2001b).
Recently an increasing body of evidence suggests a key 
role for relative estrogen defi ciency in the pathogenesis of 
male osteoporosis (Rochira et al 2006). The role of estrogen 
defi ciency in men has been disclosed during the last 10 years 
(Carani 1997; Faustini-Fustini 1999; Rochira et al 2001; 
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Rochira et al 2005). In the human male, estrogens, in particular 
the bioavailable fraction, decline with advancing age (Khosla 
et al 1998), together with the progressive fall in testosterone 
(Harman et al 2001; Khosla et al 2001B; Feldman et al 2002). 
Thus, a condition of relative estrogen defi ciency may occur 
in healthy older men as a consequence of aging, even though 
it is less severe than in postmenopausal women (Rochira 
et al 2006).
Nowadays, estrogen defi ciency (severe or mild) should 
be considered one of the key steps in the promotion of bone 
loss in men (Riggs et al 1998) as well as a major determinant 
in the pathogenesis of age-related male osteoporosis (Carani 
et al 1997; Rochira et al 2000; Rochira et al 2006).
A major role of estrogens in bone mass in men has been 
clearly demonstrated by several case studies performed on 
rare reports of male congenital estrogen defi ciency in which 
BMD is reduced (Carani et al 1997; Rochira et al 2000; 
Rochira et al 2001; Rochira et al 2002; Bouillon et al 2004). 
Several studies (Slemenda et al 1997; Greendale et al 
1997; Khosla et al 1998; Barrett-Connor et al 2000; Amin 
et al 2000; Khosla et al 2001B; Szulc et al 2001; Gennari 
et al 2003; Goderie-Plomp et al 2004) suggest that relative 
estrogen defi ciency is associated with bone loss in aging 
men. Thus, relative estrogen defi ciency seems to be strongly 
involved in the pathogenesis of age-related bone loss and 
osteoporosis in men (Riggs et al 1998; Rochira et al 2006).
Specifi c risk management 
and treatment practices for the 
osteoporotic male
The management of male osteoporosis is based on a clinical 
approach that may seem easy at fi rst examination, but in fact 
has several pitfalls. The fi rst step is the attempt to prevent 
bone loss in the subgroups of subjects considered at higher 
risk for developing an open clinical osteoporosis. This implies 
that clinicians should screen subjects, with the aim of recog-
nizing the presence of one or more risk factors. A detailed 
interview should be conducted in order to gain information 
on smoking habits, alcohol consumption, physical activities, 
dietary habitudes, and sun exposure (Orwoll and Klein 1995; 
Burger et al 1998).
Questions should be designed in order to know whether 
pubertal development occurred in a normal fashion (ie, 
delayed puberty is associated with failure in peak bone 
mass achievement) or whether other concomitant conditions 
(hypogonadism, impaired thyroid function, hyperparathy-
roidism, corticosteroid treatments, vitamin-D defi ciency, 
GH defi ciency) may contribute to the pathogenesis of 
osteoporosis (Orwoll and Klein 1995; Rochira et al 
2006).
When one or more risk factors and/or concomitant condi-
tions suggest a higher risk, or the presence of osteoporosis, 
subjects should be carefully monitored in order to establish 
the degree of bone loss by performing a measurement 
of BMD (preferably by DEXA). The perfecting of less 
expensive, and more widely available techniques of BMD 
measurement, such as calcaneal or phalangeal quantitative 
ultrasound, is desirable because they would bring an eas-
ily available, radiation free, screening test, that could be 
performed without turning to highly specialized centers. 
Preliminarly studies suggest that quantitative ultrasound 
assessment is useful for predicting osteoporotic fractures in 
men, which represents a complementary procedure to DEXA 
(Gonnelli et al 2005). The evaluation of BMD by DEXA or 
ultrasound or both should be coupled to an endocrinologi-
cal evaluation (hormones, vitamins and parameters of bone 
turnover). Establishing the degree of bone loss and the degree 
of androgenization is mandatory in order to choose the best 
strategy for successive clinical schedules. When a pattern of 
osteopenia is demonstrated, physicians must prevent further 
bone loss; a condition of osteoporosis needs pharmacological 
treatments, according to the age of the subject.
Endocrine management of the older man
A mild age-related hypogonadism is commonly pres-
ent in elderly males (Boonen and Vanderschueren 2002; 
Feldman et al 2002). A reduction in bone mineralization, 
from osteopenia to severe osteoporosis, in men over 55 
years should lead the physician to a thorough check of the 
hypothalamic-pituitary-gonadal axis. Serum testosterone, 
free testosterone, luteinizing hormone (LH), follicle stimu-
lating hormone (FSH), and prolactin are mandatory in order 
to exclude hypogonadism. SHBG measurement may also be 
performed (Legrand et al 2001).
Serum estradiol determination is seldom useful in 
eugonadic subjects; its assay could be useful in older mildly 
hypogonadic males because of the possible coexistence of 
a partial estrogen defi ciency (Rochira et al 2006). Relative 
estrogen deficiency is responsible for some signs and 
symptoms of hypogonadism (Rochira et al 2005; Rochira 
et al 2006; Fink et al 2006), and it is held in account as a 
pathogenetic step towards the development of bone loss, both 
in men and in women (Riggs et al 1998; Fink et al 2006). 
Male age-related osteoporosis management should consider 
estradiol and testosterone, their bioavailable fraction, and sex 
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hormone-binding globulin (SHBG) (Legrand et al 2001). 
Unfortunately, commercially available kits for estradiol 
determination give only partial information. There is no 
universal consensus on male serum estradiol normal range, 
and as far as estradiol determination in men is concerned, 
most estradiol assay kits available do not seem appropriate 
for the lower end of male ranges, limiting their usefulness 
to highly specialized centers and within research protocols 
(Rochira et al 2006). Recently, however, several methods 
have been compared in order to establish their reliability 
in the measurement of low serum estradiol suggesting that 
extraction-based assays correlate better with mass spectrom-
etry than direct assays (Lee et al 2006). Endocrinological 
evaluation should consider also serum PTH, calcium, phos-
phorous and markers of bone turnover as fi rst line exams 
for the diagnosis of osteoporosis. Impaired thyroid function 
should also be excluded.
Prevention of bone loss
Behavioral counseling is very important in order to prevent 
bone loss both when bone is unaffected or when osteopenia 
or osteoporosis are present. Physical activity should be 
encouraged and dietary suggestions should be provided. A 
particular consideration is necessary concerning alcoholic 
beverages: although there is general agreement on the need 
for a limitation in its consumption for reasons that go beyond 
bone health, no real defi nition of “moderate” use has been 
given, leaving the matter of quantifi cation open for debate. 
The ingestion of up to 29 g per day of alcohol (Ganry et al 
2000) was positively related to trochanteric BMD. Alcohol 
not only seems to stimulate aromatization of androgens into 
estrogens (Gavaler et al 1991), but also appears to inhibit 
osteoclast activity, and by that bone resorption (Turner et al 
2001). Thus a moderate consumption of alcohol, prefer-
ably red wine (containing also estrogen-like substances) is 
advocated, while alcohol abuse should be avoided. Smok-
ing cessation is universally considered necessary (Valimaki 
et al 1994).
As far as calcium and vitamin D are concerned, a balanced 
intake of these nutritional components is advocated. Many 
European adults of both sexes have suboptimal calcium and 
vitamin D intake (Chapuy et al 1997; Lips 2001). This is of 
particular importance if we consider that there is evidence 
of a decreased calcium absorption in the intestinal lumen in 
response to vitamin D intake, an event which progresses with 
advancing age (Pattanaungkul et al 2000), thus exposing the 
elderly to an increased risk of calcium defi ciency. Moreover 
the elderly are also at risk of vitamin D defi ciency due to 
a lack of mobility and to diminished exposure to sunlight; 
furthermore the capacity of the skin to produce vitamin D
3
 
decreases with age. Although there is no universal consensus 
about dietary calcium and vitamin D supplementation, both 
have proven very important for bone health in every period 
of life (Shea et al 2002). It is obvious that any reasonable 
treatment for osteoporosis should correct calcium and vitamin 
D defi ciency fi rst. As a matter of fact these two elements 
are often used in combination with most of the available 
antiosteoporotic drugs. Recently a trial on postmenopausal 
women suggests a benefi cial effect of vitamin D and calcium 
supplementation on BMD, but doubtful effi cacy for the 
reduction of fracture risk (Jackson et al 2006), thus leaving 
the opportunity of treatment with calcium plus vitamin D 
somewhat controversial.
Pharmacological treatments for male 
osteoporosis
Many uncertainties remain about the understanding of the 
mechanism of bone pathology and the effects of sex steroids 
therein. This uncertainty is refl ected in the various clinical 
approaches taken by physicians to treat male osteoporosis, 
that is, strategies for clinical evaluation, prevention, diagnosis 
and consideration of therapeutic options.
Many different treatments for male osteoporosis have 
been tested, although most studies are centered on post-
menopausal osteoporosis in women (Rochira et al 2006). 
Apart from counseling and nutrients supplementation, 
pharmacological treatment may help in preventing bone loss 
and in reducing the risk of fractures. Cost-benefi t analysis 
of pharmacological treatments mean that these are reserved 
for subjects with a high risk of developing osteoporosis or 
fractures. However there is wide consensus on the pharmaco-
logical treatment of men with one or more previous fractures, 
in order to prevent further events.
When men without fractures are taken into account, BMD 
should be considered, but treatment should be reserved only 
for severe osteoporosis or mild osteoporosis with more than 
one of the other risk factors (smoking, alcohol abuse etc).
Calcitonin, a polypeptide hormone which has the effect 
of decreasing osteoclast activity (DeSantis and Buchman 
2002), has also been used as an antiosteoporotic agent, but 
its effi cacy in preventing bone loss is unclear and is less than 
that of bisphosphonates (McClung 2003). For this reason 
it is no longer considered a fi rst-line treatment. Calcitonin 
treatment represents a classical therapy of osteoporosis used 
in the past and is of historical importance only.
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Bisphosphonates are presently the most widespread 
treatment for osteoporosis available. Alendronate in 
particular, shown to signifi cantly increase spine, hip, and 
total-body BMD, thus helping to prevent fractures and height 
loss in osteoporotic men, (Orwoll et al 2000) has a more 
signifi cant effect when compared with alfacalcidiol plus 
calcium supplementation (Ringe et al 2001), or with calcium 
supplementation alone (Gonnelli et al 2003).
Teriparatide, a recombinant 1–34 human PTH was more 
recently tested in men, including hypogonadal subjects, 
showing anabolic effects on bone mineralization especially at 
lumbar spine level (Orwoll et al 2003), but without substantial 
difference between hypo- and eugonadal subjects. Other fac-
tors, such as smoking, alcohol intake or basal BMD values 
appeared to diminish its effect. The peculiarity of this drug is 
that it stimulates bone formation when used discontinuously, 
while it promotes bone resorption when used for prolonged 
times (Honeywell et al 2003).
One of the most recent additions to the arsenal of anti-
osteoporotic drugs is strontium ranelate. In vitro and in 
vivo studies, the latter for the most part focused on mice, 
show promising results: strontium atoms, maybe through 
the interaction with calcium-sensing receptors, seem to be 
able to enhance osteoblastic replication and activity, while 
reducing pre-osteoclast differentiation and osteoclast activity 
(Canalis et al 1996; Baron and Tsouderos 2002; Takahashi 
et al 2003; Hott et al 2003; Amman et al 2004). The results 
in post-menopausal women show a good BMD response 
together with bioptical evidence of normal bone formation 
(Meunier et al 2004; Reginster et al 2005).
Other agents used in osteoporosis treatment include 
recombinant human growth hormone and selective estrogen 
receptor modulators but they have several limitations, 
especially in the male.
Use of androgens
Studies on the role of estrogen in human male bone patho-
physiology have in part established a lesser role that previ-
ously pertained to androgens (Vanderschueren et al 2004; 
Rochira et al 2006). A direct action of androgens on bone 
cannot be excluded. Indeed hypogonadism in men is almost 
constantly associated with an impaired BMD (Finkelstein 
et al 1992; Finkelstein et al 1996; Benito et al 2003) and 
hypogonadism represents a frequent cause of secondary 
osteoporosis in the young man (Orwoll and Klein 1995). 
Accordingly in elderly men the occurrence of a mild to severe 
androgen defi ciency could lead, directly or indirectly to bone 
loss (Boonen and Vanderschueren 2002).
Age-related hypogonadism or late onset hypogonadism 
(LOH) is “a clinical and biochemical syndrome associated 
with advancing age and characterized by typical symptoms 
and a defi ciency in serum testosterone levels” (Nieschlag 
et al 2005) which can result in a signifi cant detriment to 
quality of life (Table 1). When osteopenia or osteoporosis 
is coupled with concomitant hypogonadism the latter should 
be treated in order to restore normal circulating levels of 
testosterone (Nieschlag et al 2005). Accordingly, testoster-
one replacement treatment proved its effi cacy in improving 
the BMD both in the lumbar spine and in the femoral neck 
in hypogonadal men (Behre et al 1997; Snyder et al 2000), 
more than other non-aromatizable androgens (Crawford 
et al 2003). Nevertheless we cannot distinguish between the 
direct role that testosterone has from the effects carried out 
by its metabolites: estradiol and 5alpha-dihydrotestosterone 
(DHT). Bone tissue is known to express type 1 steroid 5alpha-
reductase which catalyses the conversion of testosterone to 
DHT. The activity of the latter on androgen receptor is more 
potent (Compston 2002), but the pharmacological blockade 
of 5alpha-reductase with fi nasteride was not able to produce 
any notable effects on bone turnover markers, nor on BMD 
(Tollin et al 1996; Amory et al 2004). This evidence indi-
rectly shifts attention from a direct androgen action on bone 
homeostasis to an estrogen-mediated mechanism of action 
(Meier et al 2004), as mentioned earlier (see the paragraph 
above on natural history and clinical presentation).
The diagnosis of hypogonadism relies mainly on the 
measurement of total blood testosterone (Bhasin et al 1998; 
Table 1 Age-related hypogonadism: defi nition, diagnosis and treatment
Defi nition Late onset hypogonadism (LOH) is “a clinical
 and biochemical syndrome associated with
 advancing age and characterized by typical symp-
 toms and a defi ciency in serum testosterone
 levels”
Signs and  Mood changes with decreased intellectual activity, 
symptoms cognitive functions, sleep disturbances, dimin-
 ished libido and erectile disfunction, decreased
 lean body mass with an increase in visceral fat;
 decrease of bone mineral density associated with
 osteopenia, osteoporosis, and increased risk of
 bone fractures
Available  Subdermal, transdermal, intramuscular, oral,
preparations buccal
Contraindications Prostate or breast carcinoma, severe polycythe-
absolute mia, severe heart failure, bladder outfl ow obstruc-
 tion or high IPSS scores
Contraindications Moderate obstruction due to a clinically benign,
minor enlarged prostate
Derived from Nieschlag et al 2004, 2005.
Clinical Interventions in Aging 2007:2(3)310
Madeo et al
Basaria and Dobs 2001; Blum and Harris 2003). Other 
assays are available, such as free testosterone or bioavailable 
testosterone measurements, but these methods need further 
attention to improve their repeatability and availability. 
Although there is no universal acceptance of the lower 
limits of normality for serum testosterone, it is generally 
well accepted that serum testosterone below 8 nmol/L (231 
ng/dL), or free testosterone below 180 pmol/l (52 pg/mL) 
require substitution even in the elderly (Nieschlag et al 2005). 
Symptoms often appear at a higher threshold, increasing the 
importance of a careful clinical evaluation to obtain a proper 
diagnosis and, eventually, for treatment. Accordingly, there 
is a substantial number of relatively asymptomatic elderly 
men whose serum testosterone levels fall below the range 
of values considered to be normal in younger adults. These 
aspects mean that the condition can often be underestimated, 
especially in the elderly, and represents the main pitfall for a 
correct diagnosis. One of the most important aspects involved 
in the failure of a correct diagnosis in older men is related to 
the frequent association of other diseases. The consequent 
need for many different specialists may be detrimental 
for an adequate approach to hypogonadism, which risks 
being underdiagnosed. For this reason an endocrinological 
evaluation is recommended. As a golden rule, testosterone 
replacement should be considered only in those hypogonadal 
men who complain about any combination of the signs and 
symptoms reported in Table 1 (Nieschlag et al 2005), or 
with markedly decreased testosterone levels (Gruenewald 
and Matsumoto 2003).
No studies have established the threshold for serum 
testosterone below which BMD may be affected, or if this 
value should be related to serum estradiol. Thus, when mild 
hypogonadism is diagnosed in the absence of any other sign 
or symptom of hypogonadism except for a reduced BMD, 
the advisability of treatment is questionable and clinical 
monitoring remains mandatory. Testosterone substitution 
should be started when severe osteoporosis is present, 
or when osteopenia is coupled with severe testosterone 
defi ciency and/or the presence of other signs and symptoms 
of hypogonadism (Table 1) (Tenover 1999; Swerdloff and 
Wang 2002; Jockenhovel 2004).
The main contraindications to testosterone replacement 
therapy include the suspicion of prostate or breast carcinoma, 
severe polycythemia, pulmonary obstructive diseases, severe 
heart failure, bladder outfl ow obstruction or high IPSS scores 
(Table 1). Moderate obstruction due to a clinically benign, 
enlarged prostate is not, per se, an absolute contraindication 
(Table 1). Those men successfully treated for prostate carci-
noma, after a prudent interval, and with no signs of residual 
cancer are candidates for substitution.
The traditional form of substitutive therapy is the intra-
muscular injectable long-acting testosterone esters prepara-
tion, but several other formulations are available (Table1). 
Transdermal testosterone gel (a hydroalcoholic gel) applied 
to intact, clean, and dry skin proved effi cacious in maintain-
ing physiological levels of serum testosterone throughout a 
day. The gel preparation is usually well tolerated and with 
fewer side effects compared with the more traditional patch 
application, thanks to its lower standard daily dosage than 
those of other preparations; it is preferable for older men 
whose serum testosterone is only slightly reduced (Swerdloff 
and Wang 2002; Steidle et al 2003). While all these methods 
have proven their effi cacy in restoring normal testosterone 
levels, their availability and affordability are not universal.
The many available preparations should be carefully cho-
sen through the adequate understanding of their pharmacoki-
netics, and possibly selected by a joint decision of the patient 
and the physician; the most appropriate therapeutic goal is 
obtaining a serum testosterone level between mid-to-low 
young male levels. Gel preparations are the best choice for 
the treatment of older men since they ensure normal circu-
lating testosterone, excluding the risk of over-treatment. 
Supraphysiological levels should be avoided, and the onset 
of contraindications during the treatment require its rapid 
discontinuation (Nieschlag and Behre 1998).
Testosterone supplementation can increase BMD in 
hypogonadal men, as widely documented in literature 
(Crawford et al 2003; Amory et al 2004; Benito et al 2005) 
and as recently confi rmed by a well-performed meta-analysis 
(Isidori et al 2005).
Screening exams can be used to monitor the possible 
side effects of testosterone treatment. Thus, PSA levels and 
hematocrit should be checked every 3 or 4 months for the fi rst 
year of substitution, then annually. Digital rectal examination 
(DRE) is indicated every 6 to 12 months from the start of 
treatment. Serum testosterone should be carefully monitored 
after 3 months since the onset of the replacement treatment, 
and every six months thereafter.
Conclusion
Age-related osteoporosis in men requires more attention 
than in the past, both in clinical practice and in research. 
Better knowledge in the future of both the pathophysiol-
ogy and natural history of osteoporosis in men will lead to 
well-established strategies for both clinical management 
and treatments.
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Further efforts are needed to differentiate subjects who 
do not require frequent medical consultation, from those who 
need careful monitoring in order to select which are the sub-
groups of patients who need pharmacological treatment.
In clinical practice, estradiol and testosterone must be 
considered, particularly with regard to their bioavailable 
fraction, together with SHBG, for the clinical evaluation of 
male hypogonadism in the elderly.
Hypogonadism in elderly men should receive greater 
attention in order to ensure replacement treatment for subjects 
with pathological levels of circulating androgens.
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